选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者：BCR - ABL突变状态是否真的重要？
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者：BCR - ABL突变状态是否真的重要？
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
应用推荐